COMP <GO>
DGX vs UNH // 10Y YIELD & FRED MACRO BETA
Quest Diagnostics Incorporated (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: DGX 8
— UNH 6
▲ 10Y YIELD & FRED MACRO BETA LEADER: DGX
LAST: $251.82 (-0.43%) • MKT CAP: $27.83B
macro-sensitivity
1.01
LAST: $406.97 (-0.96%) • MKT CAP: $368.83B
macro-sensitivity
0.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DGX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DGX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.20% | 88.57% | -55.37 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.30% | 11.47% | -1.17 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 16.4x | -0.15 | DGX | /valuation <GO> |
| Free Cash Flow Yield | 4.88% | 6.48% | -1.60 | UNH | /fcf-yield <GO> |
| Operating Margin | 14.10% | 4.82% | +9.28 | DGX | /operating-margins <GO> |
| Net Profit Margin | 9.00% | 3.14% | +5.86 | DGX | /net-margins <GO> |
| Revenue Growth (YoY) | 11.80% | 6.46% | +5.34 | DGX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.27% | 2.28% | -1.01 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.01 | 3.12 | +0.89 | DGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | DGX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.4 | 59.2 | +10.20 | DGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.01 | 0.33 | +0.68 | DGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.1x | 17.7x | +8.36 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.83B | $368.83B | -$341.00B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DGX REV | UNH REV | DGX GROSS % | UNH GROSS % | DGX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.04B | $447.57B | 33.2% | 88.7% | $1.36B | $16.07B |
| FY 2024 | $9.87B | $400.28B | 32.9% | 88.3% | $909.0M | $20.70B |
| FY 2023 | $9.25B | $371.62B | — | 89.6% | $855.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DGX // BETA 1.01
UNH // BETA 0.33